Centessa Pharmaceuticals plc (LON:0ACX)
23.60
+0.40 (1.73%)
At close: Feb 12, 2026
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M USD in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
226.04
Revenue / Employee
$131.58K
Employees
114
Market Cap
2.52B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Morgan Sindall Group | 4.70B |
| Quilter | 4.63B |
| Vistry Group | 3.69B |
| International Workplace Group | 2.68B |
| Seplat Energy | 1.92B |
| QinetiQ Group | 1.89B |
| Pennon Group | 1.18B |
| TBC Bank Group | 778.79M |
Centessa Pharmaceuticals News
- 15 hours ago - Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 22 hours ago - FMR LLC's Strategic Acquisition of Centessa Pharmaceuticals Shares - GuruFocus
- 6 days ago - First Week of CNTA January 2027 Options Trading - Nasdaq
- 9 days ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally - The Motley Fool
- 14 days ago - Truist Securities Raises Price Target on CNTA to $38, Maintains Buy Rating | CNTA Stock News - GuruFocus
- 27 days ago - First Week of CNTA March 20th Options Trading - Nasdaq
- 4 weeks ago - Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting - GlobeNewsWire